Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Our basic research into genome stability explores how cells repair damaged DNA to prevent cancer. We are also interested in what happens once cancer develops, as it is becoming clear that many tumours are defective in repairing damaged DNA. Our work aims to exploit these repair defects to design novel therapies.

Our basic research into genome stability explores how cells repair damaged DNA to prevent cancer. We are also interested in what happens once cancer develops, as it is becoming clear that many tumours are defective in repairing damaged DNA. Our work aims to exploit these repair defects to design novel therapies. As a complement to this, we are using epigenetic approaches, which concern chemical changes in chromosome composition and gene expression, to understand mechanisms of inflammation and how tumours interact with the immune system. Both of these avenues of research will help us improve the clinical application of several emerging therapeutic strategies, including those that target the immune system.



Groups within this theme

Cancer Therapeutics and mRNA Dysregulation
BLAGDEN GROUP

Cancer Therapeutics and mRNA Dysregulation

Nick La Thangue
Cancer Cell Cycle

Nick La Thangue

Andrew Blackford
DNA Damage & Disease

Andrew Blackford